Rize Oncology Inc.
RZONF
$0.16
$0.1639,900.00%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -7.97% | 46.64% | 16.09% | -7.42% | 316.77% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 172.05% | 245.47% | 67.88% | -47.52% | 212.27% |
| Operating Income | -172.05% | -245.47% | -67.88% | 47.52% | -212.27% |
| Income Before Tax | -187.49% | -271.89% | -84.19% | 46.17% | -366.30% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -187.49% | -271.89% | -84.19% | 46.17% | -366.30% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -187.49% | -271.89% | -84.19% | 46.17% | -366.30% |
| EBIT | -172.05% | -245.47% | -67.88% | 47.52% | -212.27% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -48.48% | -89.29% | 2.70% | 45.68% | -450.00% |
| Normalized Basic EPS | -47.62% | -94.12% | 0.00% | 46.00% | -425.00% |
| EPS Diluted | -48.48% | -89.29% | 2.70% | 45.68% | -450.00% |
| Normalized Diluted EPS | -47.62% | -94.12% | 0.00% | 46.00% | -425.00% |
| Average Basic Shares Outstanding | 95.50% | 95.50% | 88.23% | -1.26% | -20.72% |
| Average Diluted Shares Outstanding | 95.50% | 95.50% | 88.23% | -1.26% | -20.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |